These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36370005)

  • 1. Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension.
    Schikowski EM; Swabe G; Chan SY; Magnani JW
    J Am Heart Assoc; 2022 Nov; 11(22):e026620. PubMed ID: 36370005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis.
    Badiani B; Messori A
    Heart Lung Circ; 2016 Jan; 25(1):46-52. PubMed ID: 26233257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Pulmonary Arterial Hypertension.
    Weatherald J; Varughese RA; Liu J; Humbert M
    Semin Respir Crit Care Med; 2023 Dec; 44(6):746-761. PubMed ID: 37369218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and Discontinuation of Disease-Specific Therapies for Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Qadus S; Naser AY; Ofori-Asenso R; Ademi Z; Al Awawdeh S; Liew D
    Am J Cardiovasc Drugs; 2023 Jan; 23(1):19-33. PubMed ID: 36434365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension.
    Waxman A; Chen SY; Boulanger L; Watson JA; Golden G
    J Med Econ; 2013; 16(2):298-306. PubMed ID: 23216015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evolution of pathogenetic therapy of pulmonary arterial hypertension].
    Chazova IE; Yarovoy SY; Danilov NM
    Ter Arkh; 2019 Dec; 91(12):4-9. PubMed ID: 32598582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pulmonary hypertension.
    Hoeper MM; McLaughlin VV; Dalaan AM; Satoh T; Galiè N
    Lancet Respir Med; 2016 Apr; 4(4):323-36. PubMed ID: 26975811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
    Badagliacca R; D'Alto M; Ghio S; Argiento P; Bellomo V; Brunetti ND; Casu G; Confalonieri M; Corda M; Correale M; D'Agostino C; De Michele L; Galgano G; Greco A; Lombardi C; Manzi G; Mercurio V; Mulè M; Paciocco G; Papa S; Romeo E; Scelsi L; Stolfo D; Vitulo P; Naeije R; Vizza CD
    Am J Respir Crit Care Med; 2021 Feb; 203(4):484-492. PubMed ID: 32857597
    [No Abstract]   [Full Text] [Related]  

  • 15. High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach.
    Shah NB; Mitchell RE; Proctor ST; Choi L; DeClercq J; Jolly JA; Hemnes AR; Zuckerman AD
    PLoS One; 2019; 14(6):e0217798. PubMed ID: 31170217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of riociguat in combination therapies for pulmonary arterial hypertension.
    Rahaghi FF; Trivieri MG; Sahay S
    Respir Med; 2023 May; 211():107196. PubMed ID: 36889521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Update pulmonary arterial hypertension : Definitions, diagnosis, therapy].
    Sommer N; Richter MJ; Tello K; Grimminger F; Seeger W; Ghofrani HA; Gall H
    Internist (Berl); 2017 Sep; 58(9):937-957. PubMed ID: 28819824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender-related differences in pulmonary arterial hypertension targeted drugs administration.
    Marra AM; Benjamin N; Eichstaedt C; Salzano A; Arcopinto M; Gargani L; D Alto M; Argiento P; Falsetti L; Di Giosia P; Isidori AM; Ferrara F; Bossone E; Cittadini A; Grünig E
    Pharmacol Res; 2016 Dec; 114():103-109. PubMed ID: 27771466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
    Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
    Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.